United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma

被引:11
作者
Pratt, G. [1 ]
Bowcock, S. [2 ]
Lai, M. [3 ]
Bell, S. [4 ]
Bird, J. [5 ]
D'Sa, S. [6 ]
Cavenagh, J. [7 ]
Cook, G. [8 ]
Morgan, G. [9 ]
Owen, R. [10 ]
Snowden, J. A. [11 ]
Yong, K. [6 ]
Davies, F. [9 ]
机构
[1] Univ Birmingham, Inst Canc Studies, Heart England NHS Trust, Birmingham, W Midlands, England
[2] South London Healthcare NHS Trust, Sidcup, Kent, England
[3] Myeloma UK, Edinburgh, Midlothian, Scotland
[4] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England
[5] Bristol Haematol & Oncol Ctr, Avon Haematol Unit, Bristol, Avon, England
[6] Univ Coll Hosp, Dept Haematol, London, England
[7] St Bartholomews Hosp, Dept Haematol, London, England
[8] St Jamess Inst Oncol, Dept Haematol, Leeds, W Yorkshire, England
[9] Royal Marsden Hosp, Haematooncol Unit, Sutton, Surrey, England
[10] Leeds Teaching Hosp NHS Trust, Haematol Malignancy Diagnost Serv Lab, Leeds, W Yorkshire, England
[11] Royal Hallamshire Hosp, Dept Haematol, Sheffield S10 2JF, S Yorkshire, England
关键词
Myeloma; bendamustine; UKMF; relapse; treatment; STEM-CELL TRANSPLANTATION; REFRACTORY MULTIPLE-MYELOMA; LENALIDOMIDE PLUS DEXAMETHASONE; DOSE DEXAMETHASONE; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; RESPONSE RATE; THALIDOMIDE; BORTEZOMIB; THERAPY;
D O I
10.1111/ijlh.12097
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bendamustine is a unique bifunctional alkylating agent with promising activity in myeloma. Despite the increasing number of studies demonstrating its efficacy in both the upfront and relapse settings, including patients with renal insufficiency, the optimal use of bendamustine, in terms of dosage, schedule and combination with other agents, has yet to be defined. It is currently licensed for use as frontline treatment with prednisolone for patients with myeloma who are unsuitable for transplantation and who are contraindicated for thalidomide and bortezomib. Studies in relapsed/refractory patients are currently ongoing with other combinations. Given the increasing data to date, the UK Myeloma Forum believes that bendamustine with steroids alone or in combination with a novel agent could be considered for patients with multiply relapsed myeloma. This document provides guidance for the use of bendamustine for patients with myeloma until the results of definitive studies are available.
引用
收藏
页码:20 / 28
页数:9
相关论文
共 46 条
[1]  
[Anonymous], HEMATOL J S1
[2]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[3]   Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].
Attal, Michel ;
Lauwers-Cances, Valerie ;
Marit, Gerald ;
Caillot, Denis ;
Moreau, Philippe ;
Facon, Thierry ;
Stoppa, Anne Marie ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Garderet, Laurent ;
Decaux, Olivier ;
Leyvraz, Serge ;
Vekemans, Marie-Christiane ;
Voillat, Laurent ;
Michallet, Mauricette ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Roussel, Murielle ;
Leleu, Xavier ;
Mathiot, Claire ;
Payen, Catherine ;
Avet-Loiseau, Herve ;
Harousseau, Jean-Luc .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791
[4]   Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma [J].
Berenson, James R. ;
Yellin, Ori ;
Bessudo, Alberto ;
Boccia, Ralph V. ;
Noga, Stephen J. ;
Gravenor, Donald S. ;
Patel-Donnelly, Dipti ;
Siegel, Robert S. ;
Kewalramani, Tarun ;
Gorak, Edward J. ;
Nassir, Youram ;
Swift, Regina A. ;
Mayo, Debra .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (03) :321-330
[5]   Bendamustine: Rebirth of an Old Drug [J].
Cheson, Bruce D. ;
Rummel, Mathias J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1492-1501
[6]   High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].
Child, JA ;
Morgan, GJ ;
Davies, FE ;
Owen, RG ;
Bell, SE ;
Hawkins, K ;
Brown, J ;
Drayson, MT ;
Selby, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883
[7]   Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001 [J].
Coleman, MP ;
Rachet, B ;
Woods, LM ;
Mitry, E ;
Riga, M ;
Cooper, N ;
Quinn, MJ ;
Brenner, H ;
Estève, J .
BRITISH JOURNAL OF CANCER, 2004, 90 (07) :1367-1373
[8]   Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program [J].
Damaj, G. ;
Malard, F. ;
Hulin, C. ;
Caillot, D. ;
Garidi, R. ;
Royer, B. ;
Marit, G. ;
Stoppa, A. M. ;
Banos, A. ;
Morineau, N. ;
Moreau, P. ;
Fitoussi, O. ;
Tiab, M. ;
Moreau, P. .
LEUKEMIA & LYMPHOMA, 2012, 53 (04) :632-634
[9]   Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].
Dimopoulos, Meletios ;
Spencer, Andrew ;
Attal, Michael ;
Prince, H. Miles ;
Harousseau, Jean-Luc ;
Dmoszynska, Anna ;
San Miguel, Jesus ;
Hellmann, Andrzej ;
Facon, Thierry ;
Foa, Robin ;
Corso, Alessandro ;
Masliak, Zvenyslava ;
Olesnyckyj, Marta ;
Yu, Zhinuan ;
Patin, John ;
Zeldis, Jerome B. ;
Knight, Robert D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132
[10]   Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial [J].
Facon, Thierry ;
Mary, Jean Yves ;
Hulin, Cyrille ;
Benbouker, Lofti ;
Attal, Michel ;
Pegourie, Brigitte ;
Renaud, Marc ;
Guillerm, Jean Luc Harousseau Gaelle ;
Ahletaix, Carine ;
Dib, Mamoun ;
Voillat, Laurent ;
Maisonneuve, Herve ;
Troncy, Jacques ;
Dervaux, Weronique ;
Monconduit, Mathieu ;
Martin, Claude ;
Casassus, Philippe ;
Jaubert, Jerome ;
Jardel, Henry ;
Doyen, Chantal ;
Kolb, Brigitte ;
Anglaret, Bruno ;
Grosbois, Bernard ;
Yakoub-Agha, Ibrahim ;
Mathiot, Claire ;
Avet-Loiseau, Herve .
LANCET, 2007, 370 (9594) :1209-1218